What are the investment strengths of Oramed Pharmaceuticals Inc (ORMP)?

Trading below liquidation value: 80M EV vs 203M book value assigns zero to oral insulin pipeline. Any clinical success creates massive upside. 4-year cash runway without dilution (52M cash, 12.7M burn) gives time for clinical catalysts while peers face financing pressure.

What are the investment risks for Oramed Pharmaceuticals Inc (ORMP)?

Revenue of 2M TTM with -6% 5-year growth shows no commercial traction. Pre-revenue biotech with binary trial risk. Net income of 43.9M is entirely from investment sales (38M), not operations. Operating loss of 13M is the real run-rate.

Oramed Pharmaceuticals Inc

ORMP

—

Oramed Pharmaceuticals Inc AI Insights

Informational only. Not investment advice.

As of 2025-12-12

Snapshot

Net income TTM of 43.9M on just 2M revenue driven by 38M investment sales - not operating earnings[Net Income TTM]
Trading at 0.65x book value (203M equity) with 52M cash - EV of 80M implies negative value for pipeline[Price to Book Ratio]
Cash burn of 12.7M FCF TTM vs 52M cash = ~4 years runway without dilution[Free Cash Flow TTM]

Watch Triggers

Cash and Equivalents: Falls below 30M — Would signal <2 years runway, forcing dilutive financing or partnerships
Research and Development TTM: Increases >50% or decreases >30% — R&D changes signal pipeline acceleration or abandonment
Total Revenue TTM: Exceeds 10M — Would indicate commercial progress or meaningful licensing deals

Bull Case

Trading below liquidation value: 80M EV vs 203M book value assigns zero to oral insulin pipeline. Any clinical success creates massive upside.

Enterprise ValueTangible Book ValuePrice to Book Ratio

4-year cash runway without dilution (52M cash, 12.7M burn) gives time for clinical catalysts while peers face financing pressure.

Cash and EquivalentsFree Cash Flow TTMDebt to Equity

Bear Case

Revenue of 2M TTM with -6% 5-year growth shows no commercial traction. Pre-revenue biotech with binary trial risk.

Total Revenue TTMTotal Revenue 5yr Growth TTM

Net income of 43.9M is entirely from investment sales (38M), not operations. Operating loss of 13M is the real run-rate.

Operating Income TTMSale of InvestmentNet Income TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

35%

Leverage ORMP's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Cash runway adequate for 3-4 years but binary clinical outcomes will drive valuation

1-3ymed

52M cash vs 12.7M annual burn rate
R&D spend of 5.9M TTM indicates active development
Zero debt provides flexibility for partnerships

FCF TTM: -12.7M with 52M cash positionDebt/Equity: 0.004 (virtually debt-free)R&D TTM: 5.9M (45% of operating expenses)

Valuation Context

Caveats

Public Strategies Rankings

See how Oramed Pharmaceuticals Inc ranks across different investment strategies.

Leverage ORMP's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

ORMP Fundamentals

Manufacturing → Chemical Manufacturing

Metric	Value	YoY Growth	Industry Percentile
Market Cap	$157.41M		—
Enterprise Value	$106.09M		—
P/E Ratio	3.2		—
Total Revenue - TTM	$2.0M		—
Earnings Per Share (diluted) - TTM	$1.13		—
Operating Margin - TTM	-651%	-650.5%	—
Net Margin - TTM	2,193%	+2192.6%	—
Free Cash Flow - TTM	$-12.74M		—
Return on Common Equity - TTM	0.24	+21.5%	—
Beta 5Y (Monthly)	unknown		—

ORMP Dividend History

1 dividend

2026

$0.2500

01/16/26$0.2500

ORMP Stock Splits

1 stock split

01/23/1312:1 split

ORMP SEC Filings

Filing Date	Report Date	Report Type	Filing Link
11/13/25	09/30/25	10-Q	0001213900-25-109980
08/14/25	06/30/25	10-Q	0001213900-25-076668
05/15/25	03/31/25	10-Q	0001213900-25-044193
03/27/25	12/31/24	10-K	0001013762-25-003450
11/07/24	09/30/24	10-Q	0001213900-24-095397
08/14/24	06/30/24	10-Q	0001213900-24-068992
05/09/24	03/31/24	10-Q	0001213900-24-041364
03/06/24	12/31/23	10-K	0001213900-24-020485
11/09/23	09/30/23	10-Q	0001213900-23-085310
08/10/23	06/30/23	10-Q	0001213900-23-065678
05/11/23	03/31/23	10-Q	0001213900-23-038593
03/06/23	12/31/22	10-K	0001213900-23-017837
11/10/22	09/30/22	10-Q	0001213900-22-071222
08/10/22	06/30/22	10-Q	0001213900-22-046399
05/12/22	03/31/22	10-Q	0001213900-22-026004
01/11/22	11/30/21	10-Q	0001213900-22-001563
11/24/21	08/31/21	10-K	0001213900-21-062009
07/14/21	05/31/21	10-Q	0001213900-21-036889
04/13/21	02/28/21	10-Q	0001213900-21-021393
01/14/21	11/30/20	10-Q	0001213900-21-002235
11/24/20	08/31/20	10-K	0001213900-20-038924
07/07/20	05/31/20	10-Q	0001213900-20-016864
04/06/20	02/29/20	10-Q	0001213900-20-008653
01/09/20	11/30/19	10-Q	0001213900-20-000631
11/27/19	08/31/19	10-K	0001213900-19-024940
07/10/19	05/31/19	10-Q	0001213900-19-012456
04/10/19	02/28/19	10-Q	0001213900-19-006121
01/14/19	11/30/18	10-Q	0001213900-19-000691
11/28/18	08/31/18	10-K	0001213900-18-016666
07/12/18	05/31/18	10-Q	0001213900-18-009132
04/09/18	02/28/18	10-Q	0001213900-18-004196
01/11/18	11/30/17	10-Q	0001213900-18-000390
11/29/17	08/31/17	10-K	0001213900-17-012754
07/06/17	05/31/17	10-Q	0001213900-17-007202
04/05/17	02/28/17	10-Q	0001178913-17-001061
01/11/17	11/30/16	10-Q	0001213900-17-000252
11/25/16	08/31/16	10-K	0001213900-16-018954
07/06/16	05/31/16	10-Q	0001213900-16-014744
04/06/16	02/29/16	10-Q	0001213900-16-012280
01/13/16	11/30/15	10-Q	0001213900-16-010085
11/25/15	08/31/15	10-K	0001213900-15-009096
07/01/15	05/31/15	10-Q	0001213900-15-004892
04/03/15	02/28/15	10-Q	0001178913-15-001193
01/08/15	11/30/14	10-Q	0001178913-15-000044
11/14/14	08/31/14	10-K	0001178913-14-003555
07/14/14	05/31/14	10-Q	0001178913-14-002290
04/10/14	02/28/14	10-Q	0001178913-14-001274
01/14/14	11/30/13	10-Q	0001178913-14-000149
11/27/13	08/31/13	10-K	0001178913-13-003442
07/17/13	05/31/13	10-Q	0001178913-13-002087
04/11/13	02/28/13	10-Q	0001178913-13-001073
12/26/12	11/30/12	10-Q	0001178913-12-003519
12/12/12	08/31/12	10-K	0001178913-12-003413
07/12/12	05/31/12	10-Q	0001178913-12-001916
04/04/12	02/29/12	10-Q	0001178913-12-001000
01/12/12	11/30/11	10-Q	0001178913-12-000118
11/29/11	08/31/11	10-K	0001178913-11-003216
07/13/11	05/31/11	10-Q	0001178913-11-001977
04/12/11	02/28/11	10-Q	0001144204-11-021465
01/13/11	11/30/10	10-Q	0001144204-11-002095
11/29/10	08/31/10	10-K	0001144204-10-063863
07/14/10	05/31/10	10-Q	0001144204-10-037863
04/12/10	02/28/10	10-Q	0001144204-10-019505
01/13/10	11/30/09	10-Q	0001144204-10-001814
11/25/09	08/30/09	10-K	0001144204-09-062083
07/13/09	05/30/09	10-Q	0001144204-09-036954
03/30/09	02/28/09	10-Q	0001144204-09-016824
01/13/09	11/30/08	10-Q	0001144204-09-001778
08/31/08	08/30/08	Unknown	--
05/31/08	05/30/08	Unknown	--
02/29/08	02/29/08	10QSB	0001144204-08-022062
11/30/07	11/30/07	10QSB	0001062993-08-000111
08/31/07	08/30/07	Unknown	--
05/31/07	05/30/07	Unknown	--
02/28/07	02/28/07	NT 10-Q	0001085037-07-000821
11/30/06	11/30/06	NT 10-Q	0001085037-07-000098
08/31/06	08/30/06	Unknown	--
05/31/06	05/30/06	Unknown	--
02/28/06	02/28/06	10QSB	0001085037-06-001070
11/30/05	11/30/05	10QSB	0001214782-06-000002